vs
Side-by-side financial comparison of Pasithea Therapeutics Corp. (KTTA) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
SenesTech, Inc. is the larger business by last-quarter revenue ($421.0K vs $240.7K, roughly 1.7× Pasithea Therapeutics Corp.). SenesTech, Inc. runs the higher net margin — -428.5% vs -2126.1%, a 1697.6% gap on every dollar of revenue. SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-4.5M).
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
KTTA vs SNES — Head-to-Head
Income Statement — Q4 FY2022 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.7K | $421.0K |
| Net Profit | $-5.1M | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | -1679.5% | -446.8% |
| Net Margin | -2126.1% | -428.5% |
| Revenue YoY | — | -16.0% |
| Net Profit YoY | — | -43.7% |
| EPS (diluted) | $-1.72 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $421.0K | ||
| Q3 25 | — | $690.0K | ||
| Q2 25 | — | $625.0K | ||
| Q1 25 | — | $485.0K | ||
| Q4 24 | — | $501.0K | ||
| Q3 24 | — | $482.0K | ||
| Q2 24 | — | $459.0K | ||
| Q1 24 | — | $415.0K |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | — | -446.8% | ||
| Q3 25 | — | -195.2% | ||
| Q2 25 | — | -258.2% | ||
| Q1 25 | — | -342.9% | ||
| Q4 24 | — | -250.9% | ||
| Q3 24 | — | -321.0% | ||
| Q2 24 | — | -349.0% | ||
| Q1 24 | — | -444.1% |
| Q4 25 | — | -428.5% | ||
| Q3 25 | — | -188.1% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -343.3% | ||
| Q4 24 | — | -250.5% | ||
| Q3 24 | — | -313.9% | ||
| Q2 24 | — | -345.1% | ||
| Q1 24 | — | -441.4% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | — | $-1.28 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | $-2.07 | ||
| Q2 24 | — | $-3.08 | ||
| Q1 24 | — | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.1M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $42.5M | $9.6M |
| Total Assets | $45.2M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $10.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.6M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.3M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $4.6M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.4M | $-1.7M |
| Free Cash FlowOCF − Capex | $-4.5M | $-1.7M |
| FCF MarginFCF / Revenue | -1874.2% | -398.3% |
| Capex IntensityCapex / Revenue | 38.5% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.7M | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | — | -441.2% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
